Please assess the completion status of the following clinical trial:

Trial Title: A Research Trial of Aralast in New Onset Diabetes (RETAIN)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with T1DM within the past 100 days (of enrollment)~* Positive for at least one diabetes-related autoantibody (Anti-GAD; Anti-insulin, if obtained within 10 days of the onset of insulin therapy; IA-2 antibody and/or ICA, or ZnT8.)~* Peak stimulated C-peptide level \> 0.2 pmol/mL following a mixed meal tolerance test (MMTT)~Exclusion Criteria:~* Severe active disease (chronic active hepatitis; cardiac, pulmonary disease, hepatic, renal or immunodeficiency)~* History of any bleeding or clotting factor deficiencies, or stroke~* History of vascular disease or significant vascular abnormalities~* Positive serology of exposure to (hepatitis B virus) HBV, HCV (hepatitis C virus), HIV (human immunodeficiency virus) or toxoplasmosis~* Clinically active infection with EBV (Epstein-Barr virus), CMV (cytomegalovirus), or tuberculosis(TB)~* Prior or current use of oral, inhaled or intranasal glucocorticoids, or any medication known to cause a significant, ongoing change in the course of T1DM or immunologic status~* Prior treatment with Alpha 1-Antitrypsin (Aralast NP, AAT) or hypersensitivity to alpha 1-antitrypsin or human plasma-derived products~* Current or prior (within the last 30 days) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin~* Current use of any medication known to influence glucose tolerance (e.g., beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine anti-malarial drugs, lithium, niacin)~* Females who are pregnant or lactating, or are unwilling to defer pregnancy during study participation~* IgA (immunoglobulin A) deficiency~* Uncontrolled hypertension~* Current life-threatening malignancy~* Any condition that in the investigator's opinion may compromise study participation or may confound the interpretation of the study results.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs (Type: EXPERIMENTAL): Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
- Part 1a (Aralast NP)-Subjects 8-15 Yrs (Type: EXPERIMENTAL): Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
- Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs (Type: EXPERIMENTAL): Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
- Part 1b (Aralast NP)-Subjects 8-17 Yrs (Type: EXPERIMENTAL): Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy